CNS cancer immunity cycle and strategies to target this for glioblastoma

Malaka Ameratunga; Niamh Coleman; Liam Welsh; Frank Saran; Juanita Lopez

doi:10.18632/oncotarget.24896

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

CNS cancer immunity cycle and strategies to target this for glioblastoma

Malaka Ameratunga, Niamh Coleman, Liam Welsh, Frank Saran and Juanita Lopez _

PDF | HTML | How to cite

Oncotarget. 2018; 9:22802-22816. https://doi.org/10.18632/oncotarget.24896

Metrics: PDF 1879 views | HTML 2676 views | ?

Abstract

Malaka Ameratunga1, Niamh Coleman1, Liam Welsh2, Frank Saran2 and Juanita Lopez1

1Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK

2Department of Neuro-Oncology, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK

Correspondence to:

Juanita Lopez, email: [email protected]

Keywords: glioblastoma; immunotherapy; cancer-immunity cycle; checkpoint inhibitors; clinical trials

Received: November 30, 2017 Accepted: March 11, 2018 Published: April 27, 2018

ABSTRACT

Immunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of the central nervous system (CNS) has been lacking. There are several possible reasons for the relative lack of success of immunotherapeutics in this setting, including the immune microenvironment of glioblastoma, lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system and impairment of drug delivery into the CNS through the BBB. This review utilizes the cancer-immunity cycle as a conceptual framework through which the specific challenges associated with the development of immunotherapeutics for CNS malignancies can be viewed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24896

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

CNS cancer immunity cycle and strategies to target this for glioblastoma

Abstract